Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990051 · ClinicalTrials.gov registry record · Phase 2
Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.
A Phase 2 study of Chronic Ocular Graft-versus-host Disease, sponsored by Glia.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03990051: Completed Phase 2 study of Chronic Ocular Graft-versus-host Disease, sponsored by Glia.
NCT03990051 is a Phase 2 study of Chronic Ocular Graft-versus-host Disease that has completed, run by Glia. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03990051, a Phase 2 study of Chronic Ocular Graft-versus-host Disease, has completed, sponsored by Glia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
Primary Outcome
Change in score from Baseline for worse eye. Score is 0-100 on a visual analog scale, higher values represent worse outcomes. Symptom Assessment iN Dry Eye Questionnaire. How often do eyes feel dry and/or irritated?
Conditions Studied
Interventions
- DRUG Placebo topical gel
- DRUG Pro-ocular™ topical gel
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Longwood - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2021-11-19 |
| Phase | Phase 2 |
What the finished NCT03990051 record still lists
NCT03990051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Chronic Ocular Graft-versus-host Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo topical gel is the first listed.
NCT03990051 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03990051 about?
NCT03990051 is a clinical study titled "Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.". To evaluate the safety and efficacy of Pro-ocular™ 1% topical gel administered twice daily for 70 days in reducing or eliminating symptoms and signs of chronic ocular GvHD.
What is the current status of trial NCT03990051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2019-10-17. Estimated completion is 2021-11-19.
What conditions does trial NCT03990051 study?
This clinical trial studies the following conditions: Chronic Ocular Graft-versus-host Disease.
What interventions are being tested in trial NCT03990051?
The interventions under investigation include: Placebo topical gel (DRUG), Pro-ocular™ topical gel (DRUG).
Who is sponsoring clinical trial NCT03990051?
This trial is sponsored by Glia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03990051 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Ocular Graft-versus-host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03990051's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI